Previous 10 | Next 10 |
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2023, after the market close on Feb. 28, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT...
2024-02-06 10:18:08 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Invitae (NYSE: NVTA ) stock fell as much as 78% yesterday before it was ultimately halted because undisclosed news about the firm was pending. Many investors now expect that...
Study shows ctDNA positivity is the most prognostic factor, demonstrating the potential for Signatera to redefine adjuvant treatment pathways in endometrial cancer Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Gynec...
2024-02-04 10:07:53 ET Summary Today, we revisit NeoGenomics, a cancer genetics testing company,. The company is making progress around delivering sales growth and reducing losses. The company has a potential new problem on the litigation front, however. What's ahead for...
Clinical management was altered in 100% of patients with a Signatera positive result Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in The Journal of Thoracic and Cardiovascular Surgery demonstrating the ability of Na...
2024-01-29 09:29:24 ET More on CareDx CareDx's Turmoil: Risks Appear Priced In Circling Back On CareDx, Can The Rally Continue CareDx, Inc (CDNA) Q3 2023 Earnings Call Transcript CareDX drops after jury votes in favor of Natera in patent fight (update) ...
Liability for future sales to be determined Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of Natera in its patent infringement case a...
2024-01-26 13:32:36 ET More on CareDx, Natera, etc. CareDx's Turmoil: Risks Appear Priced In Natera: Squeezing The Last Drop From NIPT Growth Engine Circling Back On CareDx, Can The Rally Continue Invitae offloads reproductive health assets to Natera ...
AMPLIFY-201, a phase I trial evaluating treatment response to the ELI-002 vaccine, is the first study to read out using ctDNA to enroll and monitor patients with solid tumors PANDA study shows ctDNA status in patients with gastric and gastroesophageal cancers is strongly associated with r...
2024-01-22 11:29:07 ET More on S&P 500 Index: S&P 500 Sets New Record High As Investors Potentially Shift Focus To Q2 2024 Market Rally Met With Outflows S&P 500: The 'Pump' Is Underway - Watch Out For The 'Dump' S&P won't get the helping hand...
News, Short Squeeze, Breakout and More Instantly...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, Aug. 14 at 12:30 pm ET | 9:30 am PT in Boston, MA. A live webcast and audio archive of...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...